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Abstract Thapsigargin is a highly potent and selective inhibitor
of sarco-endoplasmic reticulum (SERCA) family of Ca2+-
ATPases and a useful tool in research concerning the function
of intracellular Ca2+ stores. We describe here a novel fluorescent
derivative (8-O-(4-aminocinnamoyl)-8-O-debutanoylthapsigar-
gin, termed ACTA) of this compound, acting as a Ca2+-ATPase
inhibitor with a potency approaching that of thapsigargin.
Binding of ACTA to the skeletal muscle sarcoplasmic reticulum
vesicles results in a strong fluorescence enhancement, approxi-
mately 66% of which depends on ACTA association with Ca2+-
ATPase. This specific component of ACTA fluorescence is
sensitive to the E1-E2 conformational equilibrium of the pump.
The combined properties of high potency and binding-dependent
fluorescence suggest ACTA to be a useful probe for a range of
studies involving the SERCA class of ATPases.
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1. Introduction
Maintenance of a large gradient between a low cytosolic
and a high lumenal Ca2 concentration in the endoplasmic
reticulum (ER) is essential for generation of Ca2 signals in
eukaryotic cells [1]. The concentration of Ca2 within the ER
also in£uences protein synthesis [2], as well as processing and
maturation of the proteins translocating into the ER lumen
[3]. Free Ca2 concentrations within the ER are kept at the
level of several hundred micromolar to millimolar [3,4] by the
action of Ca2-ATPases. The sarco-endoplasmic reticulum
Ca2-ATPase (SERCA) family of these enzymes is well rec-
ognized today, comprising homologous products of three
genes [5]. One aspect of the high degree of structural similarity
between the SERCA pumps is their uniform sensitivity to
inhibition by thapsigargin [6]. The high potency and selectivity
of this compound has made it a widely used tool in pharma-
cological manipulations of Ca2 content of the stores in a
large variety of cells [7].
Development of thapsigargin analogues for £uorescent la-
beling of Ca2-ATPases would be of interest for a number of
applications, including studies of SERCA pump localization
in various ER compartments, screening assays for recombi-
nantly expressed Ca2-ATPase proteins, or structure-activity
studies of Ca2-ATPase enzymes. Previously described £uo-
rescent derivatives of thapsigargin have shown a⁄nities for
Ca2-ATPase at least 2 orders of magnitude lower than the
native molecule [8,9]. Here we describe a highly potent, £uo-
rescent thapsigargin analogue, 8-O-(4-aminocinnamoyl)-8-O-
debutanoylthapsigargin (designated ACTA), and demonstrate
the ability of this compound to act as a conformational probe
due to a speci¢c enhancement of its £uorescence upon asso-
ciation with the thapsigargin binding site of Ca2-ATPase.
2. Materials and methods
A detailed description of the synthesis of 8-O-(4-aminocinnamoyl)-
8-O-debutanoylthapsigargin (ACTA) is provided elsewhere [10].
Brie£y, thapsigargin was isolated from roots and seeds of Thapsia
garganica as previously described [11]. 8-O-Debutanoylthapsigargin
(Fig. 1A) was subjected to a dicyclohexylcarbodiimide-facilitated
acylation with 4-t-butoxycarbonylaminocinnamic acid to obtain 8-
O-(4-t-butoxycarbonylaminocinnamoyl)-8-O-debutanoylthapsigargin.
This compound was treated with tri£uoroacetic acid for 15 min to
obtain ACTA. The structure of ACTA was veri¢ed by 1H- and 13C-
NMR-spectroscopy, and mass spectrometry con¢rmed the molecular
mass to be 725.
Sarcoplasmic reticulum (SR) vesicles from rabbit fast twitch skeletal
muscle (expressing SERCA1 Ca2-ATPase) were prepared according
to De Meis and Hasselbach [12] and stored in N-tris(hydroxymethyl)-
methyl-2-aminoethanesulfonic acid (TES) 20 mM (pH 7.0), sucrose
300 mM, at 380‡C. Ca2-ATPase accounted for at least 50% of the
total protein in this preparation, based on the densitometric scanning
of Coomassie Blue-stained sodium dodecyl sulfate (SDS) polyacryl-
amide gels.
ATPase activity was measured as the ATP-dependent 45Ca2 up-
take to SR vesicles at 25‡C, pH 7.0. 50 Wg/ml of protein was used in
all uptake experiments except those indicated in the legend to Fig. 1D.
Triplicate SR samples were preincubated for 10 min in the uptake
medium minus ATP, in the presence of the desired concentrations
of thapsigargin or ACTA, added as 100- or 200-fold concentrated
stock solutions in dimethyl sulfoxide (DMSO; a corresponding
amount of DMSO was present in control incubations). The medium
was then completed by adding ATP (or TES for blank determina-
tions) to start the uptake reaction. The complete medium contained
in 1.0 ml (concentrations in mM): TES 20; sucrose 60; KCl 110;
MgCl2 5; K-oxalate 6; EGTA 1; 45CaCl2 0.2 (about 1 WCi/ml);
ATP 2.5 mM. (The calculated concentration of free Ca2 ions was
0.1 WM [13].) The uptake was stopped after 4 min by ¢ltering the
mixture through Whatman GF/F ¢lters (presoaked in 0.1% polyethyl-
eneimine to reduce the background radioactivity) on a Brandel Har-
vester M24 apparatus (SEMAT Technical, UK). The ¢lters were
washed immediately in an ice-cold bu¡er containing (concentrations
in mM): Tris-HCl 20 (pH 7.0); NaCl 140; MgCl2 10; and counted
using Opti-Fluor scintillation liquid (Packard Instruments, DK) at
100% e⁄ciency. The time course of the uptake was linear for at least
up to 4 min with all the protein concentrations employed.
The IC50 or EC50 values are means of the numbers obtained from
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4-parameter logistic equation ¢tting of the dose-response data (GRA-
FIT program, Erithacus Software), with the number of individual
experiments indicated in ¢gure legends.
The £uorescence measurements were carried out in a stirred, ther-
mostated cuvette of a Hitachi F-2000 spectro£uorimeter, at 10 nm
bandpass setting. Excitation and emission wavelengths of 352 nm
and 435 nm, respectively, were used in all measurements shown, ex-
cept for the emission spectra. The medium in the cuvette (2.5 ml)
consisted of (concentrations in mM): TES 20; KCl 110; MgCl2 5;
EGTA 1; SR vesicles at the protein concentration 50 Wg/ml. When
desired, total amounts of CaCl2 were included in the mixture to ob-
tain the indicated free Ca2 concentrations, calculated according to
Foºhr et al. [13]. Thapsigargin or ACTA dissolved in DMSO were
added to obtain the ¢nal concentrations indicated in the ¢gures.
The ¢nal total DMSO concentration did not exceed 1%. Unless in-
dicated otherwise, the £uorescence measurements were carried out at
25‡C, pH 7.0.
Protein concentration was determined by the £uorescamine method
[14].
3. Results and discussion
3.1. ACTA is a potent inhibitor of Ca2+-ATPase
ACTA was obtained by a substitution of a 4-amino-cinna-
moyl moiety for the C8 hydroxyl group hydrogen of 8-O-
debutanoylthapsigargin (Fig. 1A). Fig. 1B and C compare
the inhibition obtained with thapsigargin and ACTA, respec-
tively, of the ATP-dependent 45Ca2 uptake to rabbit skeletal
muscle SR vesicles under identical assay conditions. It is clear
that the chemical modi¢cation resulted only in a slight in-
crease of the ACTA IC50 (167.5 nM, S.E.M. 8.6; N = 5), as
compared with the IC50 for thapsigargin (123.1 nM, S.E.M.
3.9; N = 5). It is well established that under the conditions
when the pump activity is well expressed, the binding of thap-
sigargin to Ca2-ATPase is stoichiometric and dependent on
the enzyme concentration [15]. When the protein concentra-
tion dependence of the IC50 values for thapsigargin-mediated
and ACTA-mediated inhibitions of 45Ca2 uptake were tested,
a linear relationship was obtained for each of the substances
(Fig. 1D), with the slope ratio of ACTA to thapsigargin of
1.39. These data show that ACTA is a potent inhibitor of
Ca2-ATPase, and are consistent with the possibility of
ACTA-ATPase interaction at the site involved in the thapsi-
gargin-mediated inhibition of the pump.
3.2. The increase of ACTA £uorescence upon binding to
Ca2+-ATPase re£ects formation of the ACTA-enzyme
inhibitory complex
With the emission wavelength set to 450 nm, the excitation
spectrum of ACTA in the absence of protein displayed a
major peak at 352 nm and a minor one at 245 nm (not
shown). A series of emission spectra excited at 352 nm is
shown in Fig. 2A. The broad £uorescence peak of ACTA
0.5 WM in the absence of protein showed a maximum at 446
nm (Fig. 2A, trace 1). In the presence of SR vesicles, succes-
sive additions of ACTA resulted in a gradual increase of the
£uorescence and an apparent shift of the peak to 435 nm (Fig.
2A, traces 3^9). Excitation and emission wavelengths of 352
and 435 nm, respectively, were employed in the remaining
experiments. The £uorescence intensity was sensitive to tem-
perature: an increase was observed with decreasing temper-
ature between 37‡C and 20‡C. This e¡ect of temperature was
not investigated any further.
In view of the ability of ACTA to act as an inhibitor of
Ca2-ATPase with a potency approaching that of thapsigar-
gin, it was likely that the increase of ACTA £uorescence in the
presence of SR vesicles re£ected its association with Ca2-
ATPase at the thapsigargin binding site. To test this assump-
tion, the sarcoplasmic reticulum membranes were preincu-
bated with increasing concentrations of thapsigargin prior to
the addition of ACTA (Fig. 2B). A thapsigargin dose-depend-
ent inhibition of the £uorescence enhancement was observed,
with a residual value reached at 1 WM thapsigargin and an
IC50 = 151.7 nM (S.E.M. 10.2, N = 5). This competition by
thapsigargin with respect to ACTA binding de¢ned a major
component (approximately 66%) of the ACTA £uorescence
enhancement which might be termed speci¢c (resulting from
ACTA association with Ca2-ATPase), and a non-speci¢c re-
sidual component, re£ecting ACTA interaction with other
protein and lipid constituents of the sarcoplasmic reticulum
vesicles. Fig. 2C shows that the speci¢c component was satu-
FEBS 21108 17-11-98
Fig. 1. Comparison of Ca2-ATPase inhibition due to thapsigargin
and ACTA. A: Thapsigargin or ACTA is obtained by substitution
of butanoyl (1) or 4-aminocinnamoyl (2) moiety, respectively, for
the hydroxyl group hydrogen (shaded) in the C8-position of the 8-
O-debutanoylthapsigargin, shown on the left. B: Inhibitor concen-
tration dependence of thapsigargin-mediated inhibition of 45Ca2
uptake to SR vesicles. Mean IC50 = 123.1 nM, S.E.M. = 3.9. C: In-
hibitor concentration dependence of ACTA-mediated inhibition of
45Ca2 uptake to SR vesicles. Mean IC50 = 167.5 nM, S.E.M. 8.6 (B
and C show data and ¢tted curves from 5 individual experiments).
D: Dependence of the apparent potencies (expressed as IC50 values)
of thapsigargin (b) and ACTA (F) as inhibitors of 45Ca2 uptake
on the concentration of SR protein.
K. Procida et al./FEBS Letters 439 (1998) 127^132128
rated at about 1 WM ACTA, with an EC50 = 214.2 nM
(S.E.M. 5.7, N = 5).
In summary, the inhibition of Ca2-ATPase by ACTA with
a potency close to that of thapsigargin (Fig. 1B and C), the
competitive e¡ect of thapsigargin on the enhancement of
ACTA £uorescence with a potency similar to its potency as
an inhibitor of Ca2-ATPase (Figs. 2B and 1B), as well as the
similarity of the saturation concentrations of ACTA and
thapsigargin in binding (Fig. 2C) and binding inhibition
(Fig. 2B), respectively, supported the speci¢c enhancement
of ACTA £uorescence being due to ACTA association with
the site on Ca2-ATPase utilized by thapsigargin. Taken to-
gether with the ¢nding of the very similar apparent ACTA
a⁄nities in the binding and 45Ca2 uptake inhibition measure-
ments (Figs. 2C and 1C), these data are also consistent with
the inhibitory activity and speci¢c £uorescence change of
ACTA representing di¡erent manifestations of the formation
of the same ACTA-Ca2-ATPase complex.
3.3. The sensitivity of ACTA £uorescence to Ca2+-ATPase
conformational state
Additional con¢rmation of the speci¢c ACTA £uorescence
re£ecting the interaction of this compound with the thapsigar-
gin-binding site on Ca2-ATPase was obtained in experiments
seeking to demonstrate a dependence of this £uorescence on
the conformational equilibrium of the enzyme in the presence
of the inhibitor. The rationale behind these experiments was
that such dependence would be expected to follow the rules
elicited for the association of thapsigargin with the pump. The
structural changes of the Ca2-ATPase involved in thapsigar-
gin binding have been interpreted in terms of the E1-E2 con-
formational model [16,17] and studied in considerable detail
[18,19]. These studies have indicated that the enzyme species
responsible for the high overall a⁄nity of thapsigargin for
Ca2-ATPase is E2; i.e. the species unable to bind Ca2
with high a⁄nity. Therefore, if high-a⁄nity ACTA binding
similarly was dependent on E2 conformation, one should be
able to manipulate the rate of speci¢c £uorescence enhance-
ment, as well as the level at equilibrium, by changing the
fraction of Ca2-ATPase in the E2 state.
To test this prediction, a series of decreasing E2/E1 confor-
mational ratios was obtained by increasing the concentration
of Ca2 in the medium at two di¡erent combinations of tem-
perature and pH (Fig. 3A,B). In each case, addition of ACTA
produced a fast component of £uorescence increase, beyond
the time resolution of our experiments, followed by a slower
component rising towards a plateau value. When 2 WM thap-
sigargin was present in the cuvette prior to the addition of
ACTA, the minimal plateau level was obtained, with the rise
to this level almost exclusively consisting of the fast compo-
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Fig. 2. Increase in ACTA £uorescence upon binding to Ca2-ATPase. A: Emission spectra excited at 352 nm and obtained in the presence of
ACTA 0.5 WM alone (trace 1), SR vesicles alone (trace 2), or SR vesicles in the presence of ACTA concentrations increasing from 50 nM (trace
3) in increments of 25 nM (traces 4^8) to the total of 200 nM (trace 9). B: Concentration dependence of thapsigargin-mediated inhibition of
the £uorescence of ACTA 1 WM in the presence of SR vesicles. Mean IC50 = 151.7 nM (S.E.M. 10.2). C: Dependence of the speci¢c component
of ACTA £uorescence enhancement on ACTA concentration. Mean EC50 = 214.2 nM (S.E.M. 5.7). For the indicated ACTA concentrations in
C, points represent di¡erences between pairs of values determined in the absence and presence of 2 WM thapsigargin. In B and C, thapsigargin
was added 3 min before ACTA; data and ¢tted curves from 5 individual experiments are shown.
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nent. Thus, £uorescence increments above this minimal level
speci¢cally re£ected ACTA association with Ca2-ATPase.
Best seen in Fig. 3A and C, this speci¢c portion of the traces
with no, or the smallest amount (1.2 WM) of free Ca2 present
still contained an unresolved fast component, followed by a
slower rise. The ¢ndings in Fig. 3A and B were that the
fraction of the speci¢c £uorescence rise occurring as a fast
component, the rate of the slow component, and the plateau
level were all diminished upon increasing Ca2 concentra-
tions. These ¢ndings may be accounted for with reference to
the scheme in Fig. 3D. Following mixing with the SR vesicles,
a fast binding of ACTA takes place to the non-ATPase (thap-
sigargin-insensitive) sites as well as to that fraction of Ca2-
ATPase present in the E2 conformation. Since in the absence
of any added Ca2 this fraction is smaller at 25‡C and pH 8.0
than at 37‡C and pH 7.0 (Fig. 3B and A, respectively)
[18,20,21], a greater portion of the speci¢c £uorescence rise
occurs as the fast, temporally unresolved component in Fig.
3A than in Fig. 3B (top trace in each ¢gure). With 1 WM
ACTA previously found su⁄cient for saturation of the spe-
ci¢c binding (Fig. 2C), use of 2 WM ACTA in the experiments
of Fig. 3A and B led to a rapid depletion of the E2 species
available for the fast binding phase. After this depletion, the
slow E1CE2 transition would become rate-limiting for fur-
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Fig. 3. The sensitivity of ACTA £uorescence to Ca2-ATPase conformational state. In A, B and C, numbers adjacent to the individual £uores-
cence records indicate nominal free Ca2 concentrations (WM), calculated from the total added Ca2 as described in Section 2. Arrows indicate
addition of ACTA to ¢nal concentrations of 2 WM (A and B) or 1 WM (C). Triangles in C indicate addition of thapsigargin to the ¢nal concen-
tration 20 WM. In the records marked by ‘Tg’, thapsigargin (¢nal 10 WM) was added 3 min prior to ACTA. In A, B and C, temperature and
pH were as indicated. Each set of records is representative of 5^10 experiments. D: The proposed reaction scheme consistent with the ACTA-
Ca2-ATPase interaction at the thapsigargin-binding site and with the observed sensitivity of the speci¢c ACTA £uorescence to the ATPase
conformational equilibrium.
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ther ACTA binding and £uorescence increase. Increasing con-
centrations of Ca2 will be expected to decrease the availabil-
ity of free E1 for the conversion to E2 and to slow it down, as
well as to decrease the total amount of E2-ACTA complex at
equilibrium, as indeed observed in Fig. 3A and B. It may also
be seen that under the conditions relatively more favorable to
the E2 conformation (i.e. 37‡C and pH 7.0 rather than 25‡C
and pH 8.0), higher Ca2 concentrations were necessary
for comparable degrees of inhibition of speci¢c ACTA £uo-
rescence rise, consistent with the decrease in the apparent
a⁄nity of Ca2 for the enzyme when the E2 conformation is
favored.
This interpretation of the ACTA binding in terms of the
equilibrium between the two distinct conformational states E1
and E2 is analogous to the interpretation of the changes in the
intrinsic Ca2-ATPase £uorescence upon binding of thapsi-
gargin presented earlier by Sagara et al. [18]. Most clearly
this analogy may be seen by referring to Fig. 7 of their report,
in which the various ratios between the fast and the slow
components of the intrinsic £uorescence change were inter-
preted in terms of the shifting equilibrium between the E2
and E1 conformational states, the slow component re£ecting
the rate of isomeric conversion to E2 driven by thapsigargin
binding.
In agreement with the scheme of Fig. 3D, Fig. 3C shows
that when ACTA concentration was decreased from 2 to
1 WM, the inhibitory e¡ect of Ca2 on the speci¢c ACTA
£uorescence rise was more pronounced (compare with Fig.
3A). Fig. 3C also shows that dissociation of ACTA could
be revealed when at the point of binding steady-state, a
20-fold excess of thapsigargin was added to prevent the re-
association of ACTA with the enzyme.
3.4. Concluding remarks
To our knowledge, this is the ¢rst report describing a thap-
sigargin analogue whose £uorescence increases strongly upon
its association with the thapsigargin binding site on Ca2-
ATPase. Fluorescent thapsigargin derivatives obtained by
replacing the butanoyl moiety with N-dansylglycine or eosin
in the C8 position of thapsigargin were described earlier [9].
While dansylthapsigargin proved useful for a study of the
£uorescence energy transfer between the tryptophanyl residues
in the membrane-bound region of Ca2-ATPase and the
enzyme-bound £uorophore [9], the e¡ect of binding on the
£uorescence of directly excited dansylthapsigargin was not
considered. However, the relatively low potency of dansyl-
thapsigargin as Ca2-ATPase inhibitor (200-fold less com-
pared to thapsigargin) would suggest that a detection of bind-
ing-related changes in its £uorescence might be di⁄cult, given
the excess of uncomplexed, £uorescent ligand. In contrast, the
high a⁄nity of ACTA for Ca2-ATPase (Fig. 1C,D, Fig. 2C),
along with an approximate 2:1 ratio between the maximal
speci¢c and non-speci¢c components of its £uorescence en-
hancement at the saturating ACTA concentration (Fig. 2B),
allowed convenient measurements of the £uorescence changes
due to ACTA-ATPase binding.
The SR vesicles from rabbit fast twitch muscle employed
here contain SERCA1 pump. Thapsigargin has proved an
equally potent inhibitor of SERCA1a, SERCA2a, SERCA2b
and SERCA3 isoforms [15], and the region of SERCA1 (S3^
M3) implicated in thapsigargin binding [22,23] is highly con-
served among SERCA1^3 subtypes [22]. Therefore, it would
seem reasonable to expect ACTA to display similar properties
when binding to other proteins of the SERCA family.
Our experiments did not directly address the underlying
physical basis for the £uorescence behavior of ACTA mole-
cule. Nevertheless, this behavior seems consistent with the
available evidence concerning the topology of the Ca2-ATP-
ase thapsigargin binding site. Bound thapsigargin has been
suggested to occupy a position within the membrane at the
lipid-protein interface [24], while speci¢cally interacting with
the near-membrane portion of the S3 segment [23]. Therefore,
ACTA binding at this site might involve a number of micro-
environmental e¡ects with a potential to a¡ect the £uores-
cence yield of its aromatic £uorophore, including e¡ects ex-
erted by site polarity, changes in ligand solvation, or ligand
structure geometry [25].
Among the possible future applications of ACTA, its be-
havior as a conformational probe might be of particular in-
terest in studies of structure-function relationships in Ca2-
ATPase. For instance, in the dissection of functional Ca2-
ATPase domains by directed mutagenesis it is sometimes nec-
essary to di¡erentiate possible displacements of E1-E2 equilib-
rium from other mutation-induced e¡ects [26]. This type of
di¡erentiation would be facilitated by the conformational sen-
sitivity of ACTA £uorescence, allowing the conformational
information to be obtained in a manner not necessarily de-
pendent on other properties of the studied mutants, e.g. the
properties of their phosphorylation reactions.
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